

Table I. Activity of 4'-Deoxydaunorubicin (3) and 4'-Deoxyadriamycin (4) on L1210 Leukemia in Mice<sup>a</sup>

Compd	Optimal dose <sup>b</sup>	T/C <sup>c</sup>	LST <sup>d</sup>
Daunorubicin	2	162	
3	4	162	
Adriamycin	5	155	2/10
4	4	177	2/10

<sup>a</sup> Tumor inoculum 10<sup>5</sup> cells, ip. <sup>b</sup> Treatment ip on day 1 (mg/kg of body weight). <sup>c</sup> Average survival time expressed as percent of untreated controls. Median survival time of untreated controls was 9 days. <sup>d</sup> Long-term survivors (60 days). No toxic deaths were observed at optimal doses indicated.

Table II. Comparison of 4'-Deoxyadriamycin (4) with Adriamycin on Solid Sarcoma 180 in Mice

Compd	Dose <sup>a</sup>	Tumor growth <sup>b</sup>	T/C <sup>c</sup>
Adriamycin	1.6	52	95
	2	51	184
4	0.8	47	90
	1	46	143

<sup>a</sup> Treatment iv on days 1-5 (mg/kg/day). <sup>b</sup> Tumor size evaluated in live animals on day 11 after tumor implant expressed as percent of untreated controls. <sup>c</sup> Average survival time expressed as percent of untreated controls. Median survival time of untreated controls was 22 days.

**Acknowledgments.** The authors are indebted to A. Di Marco and A. M. Casazza of the Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, for the biological data; to A. Vigevani and B. Gioia for the interpretation of the <sup>1</sup>H NMR and mass spectra; and to A. Alemanni for elemental analysis.

#### References and Notes

- (1) S. K. Carter, *J. Natl. Cancer Inst.*, **55**, 1265 (1975).
- (2) F. Arcamone, S. Penco, and A. Vigevani, *Cancer Chemother. Rep.*, **6**, 123 (1975).
- (3) F. Arcamone, S. Penco, A. Vigevani, S. Redaelli, G. Franchi, A. Di Marco, A. M. Casazza, T. Dasdia, F. Formelli, A. Necco, and C. Soranzo, *J. Med. Chem.*, **18**, 703 (1975).
- (4) F. Arcamone, A. Bargiotti, G. Cassinelli, S. Penco, and S. Hanessian, *Carbohyd. Res.*, **46**, C3 (1976).
- (5) F. Arcamone, A. Bargiotti, A. Di Marco, and S. Penco, British Patent Application 18098/75 (April 30, 1975); S. Hanessian and J. Banoub, *Carbohyd. Res.*, **44**, C14 (1975), and references cited therein.
- (6) F. Arcamone, G. Franceschi, and S. Penco, U.S. Patent 3803 124 (April 9, 1974).

Federico Arcamone,\* Sergio Penco, Silvio Redaelli  
Farmitalia, Ricerca Chimica, Milano, Italy

Stephen Hanessian  
Department of Chemistry, University of Montreal  
Montreal, Quebec, Canada

Received June 23, 1976

## Additions and Corrections

### 1968, Volume 11

**Girgis M. Bebawi and J. P. Lambooy:** Synthesis of Substituted 4-Dimethylaminoazobenzenes and a Study of Their Effect on *Lactobacillus casei* and *Escherichia coli*.

Page 580. In column 2, line 1, "certainty on complete" should read certainty or complete.

Page 581. In Table I under Composition, the sixth formula should be C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>, the seventh formula C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>, and the eighth formula C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>.

### 1975, Volume 18

**W. J. Wechter, M. A. Johnson, C. M. Hall, D. T. Warner, A. E. Berger, A. H. Wenzel, D. T. Gish, and G. L. Neil:** *ara*-Cytidine Acylates. Use of Drug Design Predictors in Structure-Activity Relationship Correlation.

Page 342. In column 2, line 23 should read law ( $A = Ebc$ , where  $A$  is the absorbance,  $E$  the molar extinction coefficient, etc.). In line 27, the equation should read

$$P = c_{O/W}/c_{W/O} = \frac{(A_O)(E_W b_W)}{(A_W)(E_O b_O)}$$

In line 29, the equation should read

$$P = A_O E_W / A_W E_O$$

**Norman J. Santora and King Auyang:** Non-Computer Approach to Structure-Activity Study. An Expanded Fibonacci Search Applied to Structurally Diverse Types of Compounds.

Page 960. In column 2, line 1, "point number 19" should read point number 14.

**Arthur A. Santilli, Anthony C. Scotese, and John A. Yurchenco:** Synthesis and Antibacterial Evaluation of 1,2,3,4-Tetrahydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid Esters, Carbonitriles, and Carboxamides.

Page 1041. To ref 7 should be added, A. A. Santilli and A. C. Scotese, U.S. Patent 3853 864 (1974), which specifically describes the preparation of methyl 2-chloro-6-methylnicotinate.

**Gilda H. Loew and J. Randal Jester:** Quantum Chemical Studies of Meperidine and Prodine.

Page 1054. Figures 4 and 5 are mistakenly identical. While the captions of each are correct, Figure 4 itself is wrong. Below is the correct Figure 4.